| 22 Février 2018
All countries in the seven major markets (7MM*), with the exception of Germany, will see an increase in the diagnosed prevalence cases of Crohn’s disease. France is projected to have the highest Annual Growth Rate (AGR) of diagnosed prevalent cases of Crohn’s disease at 4.04%, almost double the overall AGR of the 7MM at 2.09%. Germany, in contrast with the other markets, will see a decrease in patient size for Crohn’s disease, according to GlobalData, a leading data and analytics company.
Crohn’s disease is an inflammatory bowel disease (IBD), characterized by chronic inflammation of the gastrointestinal tract (GI). The inflammation is usually found at the end of the small intestine and at the start of the large intestine.
Nanthida Nanthavong, Healthcare Analyst at GlobalData, comments: “It is unclear why France is expected to see the highest rise in prevalent cases of diagnosed Crohn’s disease. In France, the prevalence in both men and women is expected to increase, as is the underlying population. Historically, the changes in the frequency of Crohn’s disease have been thought to be a result of environmental factors.”
The largest increases are expected in the US, France, and Japan, driven by both increases in the prevalence of Crohn’s disease and by population changes. In France, the prevalence of Crohn’s disease is higher in women compared with men. The prevalence in women rose from 0.10% to 0.14% from 2006 to 2016. For men, the prevalence rose from 0.07% to 0.10%. Variations in sex-specific prevalence may have to do with differences in risk factors that vary by sex.
* 7MM = US, 5EU (France, Germany, Italy, Spain, UK) and Japan
